Sign In
Buy PDSB
$1.08
-0.0800 (-6.90%)
At Close: Jun 03, 2026
PDS Biotech Announces Scheduling of Type C Meeting with U.S. Food and Drug Administration (“FDA”)
08:30am, Tuesday, 02'nd Dec 2025
Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Potential Accelerated Approval Pathway Company to Discuss Proposed Amendment to Phase 3 VERSATILE-003 Trial Enabling Poten
PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript
10:11am, Thursday, 13'th Nov 2025
PDS Biotechnology Corporation ( PDSB ) Q3 2025 Earnings Call November 13, 2025 8:00 AM EST Company Participants Frank Bedu-Addo - President, CEO & Director Lars Boesgaard - Principal Financial & Accou
PDS Biotech Reports Third Quarter 2025 Financial Results and Provides Clinical Programs Update
07:30am, Thursday, 13'th Nov 2025
Company Announced Completion of VERSATILE-002 Phase 2 trial of PDS0101 + Pembrolizumab in HPV16-Positive Recurrent/Metastatic Head and Neck Cancer
PDS Biotechnology Announces up to $11.1 Million Registered Direct Offering
03:31pm, Tuesday, 11'th Nov 2025
PRINCETON, N.J., Nov. 11, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
Translational study shows that multiple immunological biomarkers predict the clinical activity of PDS0101 combination therapy PDS01ADC reprograms natural killer (NK) cells to possess characteristics
PDS Biotech Announces Conference Call and Webcast for Third Quarter 2025 Financial Results
08:00am, Thursday, 06'th Nov 2025
PRINCETON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
Three abstracts accepted for presentation, including one rapid oral abstract session Presentations to highlight ongoing clinical and translational research across PDS Biotechnology's immunotherapy pla
PDS Biotech to Seek Expedited Approval Pathway for PDS0101 in HPV16-Positive Head and Neck Cancer
08:37am, Wednesday, 29'th Oct 2025
Company aims to shorten time frame to make PDS0101 available to patients with HPV16-positive head and neck cancer, projected to be the most dominant type of head and neck cancer in the US by mid 2030s
PDS Biotechnology (NASDAQ:PDSB) Trading Up 5.7% – Still a Buy?
02:18am, Tuesday, 21'st Oct 2025
PDS Biotechnology Corporation (NASDAQ: PDSB - Get Free Report) shares were up 5.7% during mid-day trading on Monday. The company traded as high as $1.03 and last traded at $0.98. Approximately 552,785
First combination therapy to report 29.5 months of Median Overall Survival (mOS); Standard of care Keytruda ® (pembrolizumab) alone (10.8 months) and Keytruda ® + chemotherapy (12.3 months) in patie
PDS Biotech to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
08:00am, Tuesday, 02'nd Sep 2025
PRINCETON, N.J., Sept. 02, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming ho
PDS Biotech Announces Final Topline Survival Data from VERSATILE-002 Phase 2 Trial in Head and Neck Cancer
08:30am, Monday, 25'th Aug 2025
Median Overall Survival (mOS) of 39.3 months in patients with CPS ≥ 1 – best published result with standard of care pembrolizumab or pembrolizumab + chemotherapy is 17.9 months*
PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call Transcript
10:08am, Wednesday, 13'th Aug 2025
PDS Biotechnology Corporation (NASDAQ:PDSB ) Q2 2025 Earnings Conference Call August 13, 2025 8:00 AM ET Company Participants Frank K. Bedu-Addo - President, CEO & Director Kirk V.
PDS Biotech Reports Second Quarter 2025 Financial Results and Provides Clinical Programs Update
07:00am, Wednesday, 13'th Aug 2025
Multiple Abstracts Presented at the 2025 American Society of Clinical Oncology Annual Meeting Conference call and webcast today at 8:00 a.m. Eastern Time PRINCETON, N.J.
PDS Biotech Announces Conference Call and Webcast for Second Quarter 2025 Financial Results
08:00am, Wednesday, 06'th Aug 2025
PRINCETON, N.J., Aug. 06, 2025 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how
